key: cord-0941638-0j2h2w6d authors: Clarke, Candice; Lucisano, Gaetano; Prendecki, Maria; Gleeson, Sarah; Martin, Paul; Ali, Mahrukh; McAdoo, Stephen P.; Lightstone, Liz; Ashby, Damien; Charif, Rawya; Griffith, Megan; McLean, Adam; Dor, Frank; Willicombe, Michelle title: Informing the risk of kidney transplantation versus remaining on the wait list in the COVID-19 era date: 2020-11-05 journal: Kidney Int Rep DOI: 10.1016/j.ekir.2020.10.032 sha: eb018a262ed3d733ad74e3b7f9757c4a2787b4c7 doc_id: 941638 cord_uid: 0j2h2w6d INTRODUCTION: There is limited data pertaining to comparative outcomes of remaining on dialysis versus kidney transplantation as the threat of COVID-19 remains. This study aims to delineate the differential risks involved using serological methods to help define exposure rates. METHODS: From a cohort of 1433 patients with ESKD, we analysed COVID-19 infection rates and outcomes in 299 wait list patients compared with 237 transplant recipients within their first year post-transplant. Patients were followed over a 68-day period from the time our transplant programme closed due to COVID-19. RESULTS: The overall mortality rate in wait list and transplant populations were equivalent, p=0.69. However, COVID-19 infection was more commonly diagnosed in the wait list patients, p=0.001, who were more likely to be tested by RT-PCR, p=0.0004. Once infection was confirmed, mortality risk was higher in the transplant patients, p=0.015. The seroprevalence in dialysis and transplant patients with undetected infection was 18.3% and 4.6% respectively, p=0.0001. After adjusting for a potential screening bias, the relative risk of death following a diagnosis of COVID-19 remained higher in transplant recipients, HR: 3.36 (1.19-9.50), p=0.022. CONCLUSIONS: In conclusion, whilst COVID-19 infection was more common in the wait list patients, a higher COVID-19 associated mortality rate was seen in transplant recipients, resulting in comparable overall mortality rates. The COVID-19 pandemic has had a dramatic impact on transplantation globally, with donation rates plummeting and many transplant centres having to temporarily close 1, 2 . As transplant activity starts to recover, the planning involved in restarting programmes amidst the ongoing threat of COVID-19 is not purely a logistical one. Although it has long been recognised that kidney transplantation offers a better prognosis over remaining on dialysis, there is limited data pertaining to comparative outcomes during the COVID-19 pandemic [3] [4] [5] . Whether there are any additional risks of acute transplantation in terms of either acquiring COVID-19 infection e.g. by nosocomial transmission, or by affecting the outcomes of infection e.g. the influence of immunosuppression, is not known. Certainly, there have been many reports of a poor prognosis in COVID-19 infected maintenance transplant recipients [6] [7] [8] [9] . What has also been identified are the unmodifiable risk factors associated with a poor prognosis, namely increasing age, ethnicity and co-morbidities including hypertension, diabetes and chronic kidney disease 10, 11 . We also know that infection rates in the dialysis population, especially in patients receiving in-centre haemodialysis (ICHD), have been high, and that this has been associated with overwhelming mortality rates [12] [13] [14] . In the absence of transferring to a home dialysis therapy, transplantation is the only other alternative option to limit hospital exposure for these patients. Therefore, data to help inform the relative risk of transplantation are required. We undertook an analysis with an aim to help delineate risk of remaining on the wait list compared with acute transplantation in the COVID era. As shown in figure 1, 3241 patients with ESKD at Imperial College Renal and Transplant Centre, London were reviewed. Wait list patients were those registered as active at the time the transplant programme closed on 18 th March 2020. We excluded patients who were registered as 'in work up', 'suspended', pre-dialysis or were receiving dialysis external to Imperial College Healthcare NHS Given the high mortality rates reported in dialysis patients, we first investigated the distinct impact of COVID-19 infection in wait list versus non-registered dialysis patients. As shown in figure 1 , 1366 patients were receiving dialysis of which 299 (21.9%) were active on the wait list with 897 (65.7%) non-registered at the time of transplant service closure. Table 1 shows the baseline characteristics of the wait list and non-registered patients. The wait list patients were younger, p<0.001; more likely to be Caucasian, p<0.0001; more likely to be undertaking dialysis therapy at home, p<0.0001 and less likely to have ESKD secondary to diabetes, p=0.0002, compared with the non-registered patients. There was no difference in the incidence of RT-PCR confirmed COVID-19 cases in the wait list There was no difference in the overall patient survival between the transplant and wait list patients Table S1 ). Given the significance difference in mortality between the transplant and wait list groups, we next There was no difference in patient survival following a diagnosis of COVID-19 between those who had previously received a transplant and those who had not, p=0.48. Multivariable analysis of factors associated with death in transplant patients was not possible. One unavoidable potential risk of undertaking transplantation is the use of immunosuppression 16 . We therefore investigated the incidence and outcome of COVID-19 infection in dialysis patients who were receiving immunotherapy either indicated for a retained failed renal transplant or an underlying autoimmune disease. One could hypothesise that these patients would be at risk of infection and a subsequent poor outcome. We found that 17.1% of our wait list patients were receiving immunosuppression but saw no increased risk in either being diagnosed with infection or death in this patient group, although the numbers are too small for conclusive interpretation. Corroboration of this observation will be clinically informative, although any analysis should consider that immunotherapeutic agents may have differential effects on COVID-19 outcomes 18, 19 . It is also important to highlight that the risk of immunosuppression in this subgroup of dialysis patients is not J o u r n a l P r e -p r o o f comparable to patients within their first year post-transplant, when the risk of any infection is at its highest 20 . In terms of optimal transplant induction regimens, both from the safety and efficacy perspective, national data sets will most likely enable the provision of evidence but whilst the threat of further waves of COVID-19 remain, bespoke immunosuppression trials may be required. When stratifying individual risk of transplantation, consideration may also be needed for type of donor. Whilst deceased donor transplants rely on an operational national infrastructure and are unpredictable for recipient 'shielding', direct living donor transplantation only requires local and elective pathways, which may be easier to predict and manage. It is also noteworthy that only 1 of the In conclusion, as services start to recover we must start planning for how transplantation and follow up care are going to look to the new era. This study provides data on the outcomes of COVID-19 in transplant recipients compared with wait list patients on dialysis in a single centre. Further data sets are required to corroborate our findings but more importantly we need to understand the patient's perspective. Personal experiences from the authors of this paper suggests that patients are looking to us more than ever to provide informed advice, which is currently unavailable in these unprecedented times. There are likely to be considerable inter-country, inter-centre and inter-patient level differences in how programmes are run, but counterintuitively only collectively will we be able to complete the rehabilitation process. J o u r n a l P r e -p r o o f Organ procurement and transplantation during the COVID-19 pandemic COVID-19 cases in wait list and organ transplant patients Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant The impact of waiting time and comorbid conditions on the survival benefit of kidney transplantation Solid organ transplantation programs facing lack of empiric evidence in the COVID-19 pandemic: A By-proxy Society Recommendation Consensus approach COVID-19 in Solid Organ Transplant Recipients: Initial Report from the US Epicenter COVID-19 in solid organ transplant recipients: a single-center case series from Spain Early Description of Coronavirus 2019 Disease in Kidney Transplant Recipients in New York Managing COVID-19 in Renal Transplant Recipients: A Review of Recent Literature and Case Supporting Corticosteroidsparing Immunosuppression Features of 16,749 hospitalised UK patients with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol. medRxiv OpenSAFELY: factors associated with COVID-19 death in 17 million patients Clinical Characteristics of and Medical Interventions for COVID-19 in Hemodialysis Patients in Wuhan Initial analysis of the impact of covid19 infection on patients with advanced chronic kidney disease in the UK Epidemiology of COVID-19 in an Urban Dialysis Center Acute cellular rejection: impact of donor-specific antibodies and C4d COVID-19 and Calcineurin Inhibitors: Should They Get Left Out in the Storm? Minimizing the risk of COVID-19 among patients on dialysis Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies SARS-CoV-2 and Multiple Sclerosis: Not all immune depleting DMTs are equal or bad Rates of first infection following kidney transplant in the United States Antibody prevalence for SARS-CoV-2 in England following first peak of the pandemic: REACT2 study in 100,000 adults Supplementary information is available at KI Report's website.